Insider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Acquires 240,000 Shares of Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri bought 240,000 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were purchased at an average price of $5.00 per share, with a total value of $1,200,000.00. Following the completion of the acquisition, the insider now owns 2,884,121 shares of the company’s stock, valued at $14,420,605. This trade represents a 9.08 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Friday, December 13th, Marlio Charles Mosseri purchased 17,000 shares of Nuvectis Pharma stock. The shares were acquired at an average cost of $4.70 per share, with a total value of $79,900.00.

Nuvectis Pharma Stock Performance

Shares of NVCT stock opened at $6.95 on Friday. Nuvectis Pharma, Inc. has a fifty-two week low of $4.44 and a fifty-two week high of $12.10. The firm has a market cap of $134.28 million, a P/E ratio of -5.99 and a beta of 0.22. The business’s 50 day moving average price is $5.70 and its 200-day moving average price is $6.34.

Institutional Trading of Nuvectis Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Baldwin Wealth Partners LLC MA raised its holdings in Nuvectis Pharma by 104.4% in the 4th quarter. Baldwin Wealth Partners LLC MA now owns 355,961 shares of the company’s stock worth $1,926,000 after purchasing an additional 181,831 shares in the last quarter. Marshall Wace LLP increased its position in shares of Nuvectis Pharma by 191.0% during the fourth quarter. Marshall Wace LLP now owns 124,571 shares of the company’s stock valued at $674,000 after buying an additional 81,757 shares during the period. Iridian Asset Management LLC CT bought a new position in Nuvectis Pharma in the third quarter worth about $348,000. Geode Capital Management LLC lifted its holdings in Nuvectis Pharma by 49.8% in the third quarter. Geode Capital Management LLC now owns 79,716 shares of the company’s stock worth $501,000 after buying an additional 26,489 shares during the period. Finally, Oppenheimer & Co. Inc. purchased a new stake in Nuvectis Pharma in the fourth quarter worth about $135,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.